135 results about "Progressive renal failure" patented technology

Systems and methods for extracorporeal processing of blood or other body fluid for the treatment of conditions, such as sepsis, autoimmune disease, or toxemia related to kidney failure, liver failure, or drug overdose are provided. In an extracorporeal treatment system, a fraction of a body fluid is passed into a treatment fluid, at least a portion of which is then passed through a sorbent suspension reactor for treatment by a sorbent suspension. The treatment fluid circuit can be maintained at a fixed volume, which enables accurate fluid balance between the patient and the extracorporeal circuit. Some or all of the treatment fluid, optionally also containing nutrients and / or therapeutic agents, is returned to the patient. In a peritoneal dialysis system, dialysate is passed into a patient's peritoneal cavity, recovered from the cavity, passed through a sorbent suspension reactor in accordance with the invention, and returned to the cavity.

A machine (1) for extracorporeal blood treatment comprises a device (2) for ultrafiltration of a liquid through a semi-permeable membrane (3) of a blood treatment device (4), a first sensor (11) for ultrafiltration rate through the membrane, a second group of sensors (13) for measuring a trans-membrane pressure, and a programmed controller (14) for calculating a maximum ultrafiltration rate as a function of the transmembrane pressure. The machine is suitable for kidney failure treatments, such as hemofiltration and hemodiafiltration. In a relatively short time the machine enables a large quantity of corporeal blood to be removed from the patient.

An early-onset method and kit for detecting renal tubular cell injury, using NGAL as an early urinary biomarker. NGAL is a small secreted polypeptide that is protease resistant and thus readily detected in urine following tubular cell injury. NGAL protein expression was mainly detected in the proximal tubule cells, which resembled a secreted protein with a punctate distribution in the cytoplasm. Apparent NGAL in urine correlates with the amount and duration of renal ischemia and nephrotoxicemia and is a diagnostic feature of tubular cell injury and renal failure. NGAL detection is also a useful marker for monitoring nephrotoxic side effects of drugs or other therapeutic agents.

Devices and methods for measuring a target ion concentration uses an electrode pair. The pair includes a working electrode and a reference electrode. The working and reference electrodes are ion-selective electrodes (ISEs). The reference ISE can include a sodium ISE. The ISE pair interacts with body fluids where a target ion concentration changes more than sodium ion concentration over time. Some ISE membranes of a pair vary essentially only in the ionophore. An ISE pair can determine the ratio of a target ion concentration to sodium ion concentration in vivo. Periodic measurement of sodium concentration in drawn blood can be used to calibrate an ISE pair and provide target ion concentration as an output. Or, a potassium / sodium ISE pair beneficially monitors potassium concentration changes over time in heart- or kidney-failure patients. Then, manual or automatic titration of a diuretic material can be implemented to maintain a desired potassium concentration.

This invention relates to a series of substituted cyclohexane containing analogues which are agonists of GPR119 intended to treat metabolic diseases mediated by GPR119 including Type I & II diabetes mellitus. Diabetes mellitus is an ever-increasing threat to human health causing various complications (blindness, kidney failure, neuropathy, heart attack, stroke, etc.). Recently it was found that activation of GPR119 which is highly expressed in pancreatic beta cells causes glucose dependent insulin secretion and GLP-1 release. Many pharmaceuticals are currently developing GPR119 agonists and herein we disclose alternative GPR119 agonists. Our invention describes GPR119 agonists having structural Formula (I), pharmaceutically acceptable salt or solvate of Formula (I), isomer or prodrug of Formula (I), and combination therapy of Formula (I) with other anti-diabetic drugs like DPP-IV inhibitors and / or insulin sensitizers.

A composite medicine for improving the curative effect of the antihypertensive medicine containing Ca channel retardant and preventing the complications such as eyeground hemorrhage, angina pectoris, myocardial infarction, cerebral apoplexy, heart failure and kidney failure is composed of Ca channel vetardant or its precursor or its active metabolite or its salt, one or more of vitamins in B family and the pharmacologically acceptable carrier.

The invention provides a preparation method of a traditional Chinese medicine for treating kidney failure, which comprises the following steps of preparing traditional Chinese medicinal raw materials, including radix pseudostellariae, rheum officinale, rhizoma coptidis, poria cocos, rhizoma pinellinae praeparata, radix salviae miltiorrhizae, 80 to 120 parts of dried orange peel, safflower, radix achyranthis bidentatae and liquorice, preparing rheum officinale powder, preparing radix pseudostellariae powder, preparing thick paste and obtaining the preparation. The invention also provides a quality inspection method of the traditional Chinese medicine, which comprises the following steps of checking according to each rule under a granule item of a pharmacopoeia, and content determination according to high performance liquid chromatography, and the rhizoma coptidis content of each granule of the traditional Chinese medicine cannot be less than 15.0mg by berberine hydrochloride C20H17NO4.HCl. The preparation process provided by the invention is reasonable in design, is advanced, and has the advantages that the characteristic of coldness of the existing medicine Shenshuaining can be effectively improved, the dissolving-out amounts of effective components of the rheum officinale and the radix pseudostellariae and the extraction rate are increased, effective components of a product are completely saved, and besides, the problems of instability and uncontrollability of the effective components of the rheum officinale and the radix pseudostellariae in the medicine are also effectively improved. The quality inspection method provided by the invention has the advantages that the stability and the controllability of the quality of the medicine Shenshuaining can be guaranteed.

The invention relates to compositions, such as pharmaceuticals, foods, food additives, or dietary supplements, containing A-type procyanidins, and methods of use thereof, for prophylactic or therapeutic treatment of a human or a veterinary animal to treat or prevent NO-responsive health conditions, treat hypertension, cardiovascular disease, coronary artery disease and / or vascular circulation disorders, prevent or reduce the risk of heart attack, stroke, congestive heart failure and / or kidney failure, or to improve blood flow, for example renal blood flow. The composition may optionally contain an additional NO modulating agent and / or a cardiovascular-protective or therapeutic agent, or may be administered in combination with such an agent.

The invention discloses a novel Chinese medicinal composition for treating kidney failure diseases and a preparation method thereof. The Chinese medicinal composition mainly comprises the following raw material medicaments: medlar, American ginseng, campanumaea pilosula, raw astragalus, pantotrichum, common yam rhizome, sea horse, medicinal indianmulberry root, cordyceps sinensis, lucid ganoderma, south dodder seed, gordon euryale seed, eucommia bark, radix rehmanniae preparata, Chinese angelica, white paeony root, cochinchnese asparagus root, glossy privet fruit, amur corktree bark, Indian buead, gardenia, plantain seed, longhairy antenoron herb, talc and oriental waterplantain rhizome. The Chinese medicinal composition can be prepared into any common oral preparation by the conventional Chinese medicinal preparation method. The Chinese medicinal composition can obviously improve symptoms such as edemaofface, edema of limbs, inability to get food down, bradypsychia, uroschesis, creatinine, albuminuria, dreaminess, insomnia and the like, and can improve various complications which seriously influence health and life and even cause depth such as infection, diseases of cardiovascular systems, nervous systems and digestive systems, electrolyte disturbance, metabolic acidosis and the like caused by renal function hydrolysis. The Chinese medicinal composition has the advantages of exact clinical effects, obvious curative effect, quick response, low cost, basically no toxic or side effects and the like because the Chinese medicinal composition basically combines medicaments having homology of medicament and food specified in national formulary.

The invention relates to a rosuvastatin calcium sustained-release preparation and a preparation method thereof. The rosuvastatin calcium sustained-release preparation basically contains 5 to 10mg of rosuvastatin calcium, and the balance of sustained-release framework material and other pharmaceutical excipients. The preparation method is simple; and all the materials are proportioned and the preparation is prepared by the preparation method for common tablets, granules or capsules. The rosuvastatin calcium sustained-release preparation prepared by the method avoids adverse reactions such as rhabdomyolysis, proteinuria, nephrosis, kidney failure, hepatotoxicity and the like caused by overdosage of medicaments; meanwhile, due blood concentration and time for treating diseases after the medicaments are taken can be maintained, and the peak valley phenomenon of the blood concentration is effectively avoided.

The invention is related to metabolically stable apelin analogs and their use for the prevention or the treatment of diseases mediated by the apelin receptor in particular of cardiovascular disease (heart failure, hypertension, pulmonary hypertension, kidney failure) and inappropriate vasopressin secretions (SIADH).

A method of determining kidney failure in a patient using an implantable medical device is described. In one embodiment, a first magnitude of a first polarization signal is measured. An additional magnitude of an additional polarization signal is measured after a first interval. A deflection differential between the first magnitude and the additional magnitude is determined and kidney failure in the patient is determined when the deflection differential is greater than an established threshold.

The present invention relates to 1-methylol imidazole [1, 2-alpha] quinolxaline compounds and their medicinal salts. These compounds and their medicinal compositions may be used as adenosine acceptor antagonist in preventing and treating depression, dysgosia, kidney failure, asthma, acute respiratory distress, arrhythmia and other symptoms.

The invention relates to a production method of special low-protein noodles for a patient with kidney failure or uremia, which belongs to the technical field of food processing. The production method comprises the following steps of: mixing low-protein corn flour and fruit and vegetable powder fully, adding purified water and controlling the water content of raw materials to be 10-80%; and adding the mixed materials into a secondary extrusion forming machine for curing and forming, cutting after drying the water content of a product to be 5-20%, packaging and sterilizing so as to obtain the product of the low-protein noodles finally. According to the special requirement of the patient with the kidney failure or the uremia, the invention adopts the low-protein corn flour as the main raw material, produces the low-protein nutritional noodles with favorable taste by powder blending, water content regulation, pre-curing and extrusion forming, is suitable for the special people of the patient with the kidney failure or the uremia and the like to eat and has a certain market development prospect, and the elements of the mineral substances of sodium, potassium, calcium, magnesium and the like of the low-protein nutritional noodles are also far lower than that of the foods of common noodles and the like.

The invention discloses culture solution for inducing mesenchymal stem cells to differentiate into glomerular mesangial cells and an inducing method. The culture solution comprises a human platelet-derived growth factor-BB, all-trans-retinoic acid, collagen-IV and a basic medium, wherein the basic medium is a low-sugar DMEM (Dulbecco's modified eagle medium) containing 2% of horse serum and 5ng / ml of bFGF (basic fibroblast growth factor). The inducing method includes the steps: preparing the inducing culture solution; preparing the mesenchymal stem cells; coating a culture plate by the collagen-IV with the concentration of 5ug / cm<2>; inoculating the mesenchymal stem cells with the cell density of 5*103 / cm<2> into the coated culture plate and adding the inducing culture solution; changing the solution once every three days and performing inducing culture for seven days. The mesenchymal stem cells are jointly induced to differentiate into the glomerular mesangial cells by the aid of the human platelet-derived growth factor-BB, the all-trans-retinoic acid and the collagen-IV, inducing period is short, inducing efficiency is high, the glomerular mesangial cells formed by differentiation are high in functional activity, and transplantation therapy of kidney diseases such as kidney failure is facilitated.

The invention discloses a novel natriuretic peptide, which is prepared through a connection of a brain natriuretic peptide and a dendroaspis natriuretic peptide, wherein the brain natriuretic peptide is on the N terminus of the novel natriuretic peptide, the snake natriuretic peptide is on the C terminus of the novel natriuretic peptide, and the brain natriuretic peptide comprises a disulfide bond cyclic structure which is composed of two cysteine residues. The preparation method comprises the following steps: obtaining a brain natriuretic peptide gene and a snake natriuretic peptide gene, connecting the two genes together to synthesize a novel natriuretic peptide gene through a PCR method; constructing an expression plasmid comprising the novel natriuretic peptide gene; and converting the expression plasmid to a proper expression bacterial strain to carry out an induction culture to induce the expression of the novel natriuretic peptide. The novel natriuretic peptide has the characteristics of the brain natriuretic peptide and dendroaspis natriuretic peptide at the same time, the specific effect is prominently strengthened, and the half-life period of drug is prominently prolonged. The preparation method has the advantages of simple technology and practicality; the gene engineering drugs having the novel natriuretic peptide can effectively act on effector organs such as heart, blood vessel, and kidney, effectively protect the functions of the organs mentioned above, prevent and treat diseases such as heart disease, kidney failure, etc.

The invention provides a traditional Chinese medicine special for treating diabetic nephropathy with chronic renal failure. The traditional Chinese medicine is prepared from the following components in parts by weight: 10 to 12% of rheum officinale, 20 to 25% of astragalus membranaceus, 10 to 12% of wine-prepared fructus corni, 10 to 12% of prepared rehmannia root, 20 to 25% of poria cocos, and 15 to 20% of rhizoma alismatis. The traditional Chinese medicine can be used for effectively and safely delaying kidney failure and glucose and lipid metabolism disorder and comprehensively treating diabetes renal complications, has an obvious treatment effect, and is low in cost.

The invention relates to a Chinese medicament for treating kidney failure, and belongs to the technical field of Chinese medicaments. The medicament for treating chronic kidney failure comprises the following active ingredients in part by weight: 10 to 20 parts of astragalus, 4 to 9 parts of heterophylly falsestarwort root, 5 to 15 parts of Indian buead, 4 to 10 parts of large-headed atractylodes rhizome, 8 to 15 parts of Chinese caterpillar fungus, 8 to 15 parts of twotooth achyranthes root, 15 to 20 parts of prepared common monkshood daughter root and 10 to 20 parts of rhubarb. The medicament for treating the kidney failure can improve the microcirculation of the kidney effectively, promote blood circulation and remove blood stasis, increase flow of renal blood and improve human immunity, has no toxic or side effect for long-term administration, does not cause medicinal tolerance, and has low cost and obvious curative effect on the kidney failure.

The present invention relates to the new use of alpha-ketoglutarate, amides, and salts and mixtures thereof for the manufacture of a pharmaceutical preparation or a food or feed supplement for the in vivo therapeutic improvement of blood vessel elasticity, in particular arterial elasticity in a subject in need thereof. Improving the blood vessel elasticity may be used in the for the treatment and / or prophylaxis of hypertension, pulmonary arterial hypertension, cardiovascular disease, retinal vascular disease, heart failure, atherosclerosis, ventricular hypertrophy, stroke, arterial aneurysm, kidney failure, nephrosclerosis and diseases related to hypertension.

The invention relates to a Chinese herbal preparation for treating nephropathy and the method and application thereof; the invention is applied in capsules, granules, powers or tablets for treating acute and chronic nephritis, nephrotic syndrome, acute and chronic pyelonephritis, uronephrosis, acute and chronic renal failure and uremia. The twelve varieties of indigents and the weights of the invention are as following: rhubarb of 5 to 15g, cowherb seed of 1 to 5g, laminaria japonica of 5 to 15g, menispermaceae of 4 to 12g, agalloch eaglewood of 1 to 5g, plantain seed of 5 to 15g, polyporus of 4 to 12g, americanwater plantain of 4 to 12g, RhizomaChuanxiong of 3 to 9g, safflower of 3 to 9g, glycyrrhiza of 3 to 12g and radix cyathulae of 4 to 12g. The invention has the advantages of having significant efficacy and rapid and permanent effect owing to Chinese herbal preparation, having no obvious toxic and side effect, taking medicine conveniently, significantly relieving the pain of patients, improving life quality, prolonging the life of patients, obtaining the medicine easily and having lost cost for ordinary people to pay, thereby being suitable for China. According to the study on clinic effect, the ameliorative rate of symptom is 100 percent and the clinical cure rate is over 90 percent, with significant effect to nephropathy. The invention has unique preparation method, and significance of further study and popularization.

The present invention relates to a medicine for treating chronic renal failure. The chronic renal failure is the final result of various kidney diseases, but without effective western medicine in clinic yet, and dialysis therapy and renal transplantation price are expensive and not suitable for early and middle patients. The medicine whole formula of the present invention both activates and tonifies, consideration to right and evil, nourishing and releasing integrated, leading nourishing not stagnating evil, releasing not injuring right, can not only delay chronic renal failure course, but also improve or eliminate clinical symptoms, having good curative effect, lower cost characteristic. The present invention concretely is with radix astragali, poria, hedyotis diffusa, serissa foetida, pyrola calliantha, ligusticum chuanxiong, morinda officinalis how, centella asiatica, prepared rhubarb and etc. traditional Chinese medicine to prepare into compound preparation. The present invention also relates to the medicine preparation method. As pharmacological experiment shows the present invention can obviously decrease adenine causing chronic renal failure rat and nephrectomy causing chronic renal failure rat kidney function Crea and BUN value, the present invention can also obviously increase water load rat urinary volume.

The present invention is new use of mycose sulfate in pharmaceutical field. The medicine has obvious effects of obviously lowering kidney coefficient, serum inosine and urea nitrogen level, obviously increasing total serum protein and albumin, increasing urine creatinine exhaust amount, obviously decreasing exhausted urine protein, etc. It is used in treating nephritis and kidney failure disease and has the advantages of obvious curative effect, less toxic side effect, etc.

Various types of a medical device are described which is used as an implantable renal replacement therapy (an implantable artificial kidney). This device removes toxins and excess water from blood of patients with kidney failure or end stage renal disease. Additionally, other configurations of the device can be used as an external (extracorporeal) device.

The invention discloses rice wine with kelp and coffee flavours. The rice wine consists of the following raw materials in parts by weight: 90-100 parts of rice, 10-20 parts of kelp, 4-6 parts of coffee powder, 2-3 parts of hawthorn seeds, 2-4 parts of roselle, 1-2 parts of sunflower disks, 3-5 parts of prunus humilis bunge leaves, 2-4 parts of chrysanthemums, 1-2 parts of dried mangoes, 2-3 parts of garlic cloves, 2-3 parts of dried orange peels, 0.2-0.5 part of citric acids and 10-15 parts of wine yeast. The rice wine with kelp and coffee flavours breaks through the mouth feel of the traditional rice wine, is sweet and mellow in aroma and has a very high health-care value; and the kelp contains a large quantity of mannitol which has a diuretic detumescence efficacy, so that the rice is capable of preventing and treating kidney failure, senile oedema, drug poisoning and the like. The mannitol cooperates with iodine, potassium, niacin and the like, so that the rice wine has good effects of preventing and treating diseases such as arteriosclerosis, hypertension, chronic trachitis, chronic hepatitis, anemia and oedema. The dried orange peels can play roles of regulating vital energy, appetizing, drying dampness, resolving phlegm, and treating spleen and stomach diseases, so that the rice wine has the efficacies of clearing heat, removing toxicity, moistening lung, and the like.

The invention belongs to the technical field of traditional Chinese medicines and especially relates to a traditional Chinese medicine for treating chronic renal failure. The traditional Chinese medicine comprises, by weight, 35-65 parts of rheum officinale, 5-10 parts of prepared leech, 10-20 parts of prepared peach seed, 10-20 parts of prepared ligusticum wallichii, 10-15 parts of pseudo-ginseng, 10-15 parts of processed pangolin and 10-15 parts of centipede. The raw materials are not burdensome, are comprehensive and considerate, produce effects of promoting blood circulation to remove blood stasis, and have effects of diminishing inflammation, effectively improving kidney blood stasis, recovering normal functions of kidney and curing kidney failure.

The bifurcated peritoneal catheter serves as a peritoneal dialysis device for patients with kidney failure. The catheter includes a primary tube with two porous internal tubes extending therefrom at a small acute angle to one another. The two internal tubes provide a solution to the potential problem of blockage in a single catheter tube, greatly reducing the potential need for surgery to remove and replace such a single catheter tube. The bifurcated peritoneal catheter includes a subcutaneous cuff, and can include a second deep cuff in the abdominal wall. Either or both of the internal tubes can be straight, curved or coiled, with the curvatures and coils oriented in the same direction, toward one another, or away from one another.